GlassScriptPhysician profile
Laura E Kelso
NPI 1356664262
$8,872.66
in general payments reported to CMS, 2019-2025
27 companies · $3,333 in 2025
The $3,333 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,293 · 2022: $1,119 · 2023: $1,552 · 2024: $1,574 · 2025: $3,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,490 · Consulting Fee: $2,495 · Education: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,489.91 |
| Consulting Fee | $2,495.35 |
| Education | $474.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $2,663.82 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $1,003.20 | 2021-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $836.78 | 2021-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $765.82 | 2021-2025 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $748.75 | 2021-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $624.24 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $410.45 | 2021-2025 | Jynarque |
| Akebia Therapeutics INC | $214.50 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $211.69 | 2021-2023 | Acthar |
| Amgen INC. | $188.95 | 2021-2025 | Tavneos, Parsabiv, Aranesp |
| Travere Therapeutics, INC. | $168.76 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $166.79 | 2021-2024 | Lupkynis |
| Ultragenyx Pharmaceutical INC. | $140.70 | 2022-2024 | Crysvita |
| Abbott Laboratories | $136.93 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $87.54 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $79.67 | 2024-2025 | Crysvita |
| Abiomed | $74.06 | 2024-2025 | Impella |
| Horizon Therapeutics Plc | $57.47 | 2021-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.66 | 2024 | Jardiance |
| Genzyme Corporation | $53.29 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $48.40 | 2023 | Purified Cortrophin Gel |
| Xeris Pharmaceuticals, INC. | $30.77 | 2021 | |
| Cormedix INC. | $28.17 | 2025 | Defencath |
| Lilly USA, LLC | $22.21 | 2024 | Jardiance |
| Ardelyx, INC. | $21.10 | 2023 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $16.58 | 2022 | |
| Shield Therapeutics INC | $15.36 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Kelso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.